Top

Published in:

Open Access 01-06-2021 | Antibiotic | Original Article

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

Authors: Annika Y. Classen, Larissa Henze, Marie von Lilienfeld-Toal, Georg Maschmeyer, Michael Sandherr, Luisa Durán Graeff, Nael Alakel, Maximilian Christopeit, Stefan W. Krause, Karin Mayer, Silke Neumann, Oliver A. Cornely, Olaf Penack, Florian Weißinger, Hans-Heinrich Wolf, Jörg Janne Vehreschild

Published in: Annals of Hematology | Issue 6/2021

Abstract

Hematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii pneumonia (PcP). As bacterial resistances are increasing worldwide and new research reshapes our understanding of the interactions between the human host and bacterial commensals, administration of antibacterial prophylaxis has become a matter of discussion. This guideline constitutes an update of the 2013 published guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). It gives an overview about current strategies for antibacterial prophylaxis in cancer patients while taking into account the impact of antibacterial prophylaxis on the human microbiome and resistance development. Current literature published from January 2012 to August 2020 was searched and evidence-based recommendations were developed by an expert panel. All recommendations were discussed and approved in a consensus conference of the AGIHO prior to publication. As a result, we present a comprehensive update and extension of our guideline for antibacterial and PcP prophylaxis in cancer patients.

Available only for authorised users

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 106:2258–2266PubMedCrossRef

Pagano L, Caira M, Rossi G, Tumbarello M, Fanci R, Garzia MG et al (2012) A prospective survey of febrile events in hematological malignancies. Ann Hematol 91:767–774PubMedCrossRef

Cordonnier C, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A et al (2016) Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71:2379–2385PubMedCrossRef

Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol

Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRef

Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998PubMedCrossRef

Hidalgo M, Mendiola C, Lopez-Vega JM, Castellano D, Mendez M, Batiste-Alenton E et al (1998) A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group. Spain Cancer 83:719–725PubMedCrossRef

Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 90:4710–4718PubMedCrossRef

Truong J, Lee EK, Trudeau ME, Chan KK (2016) Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol 27:608–618PubMedCrossRef

10.

Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fatkenheuer G, Wisplinghoff H et al (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 40:613–619PubMedCrossRef

11.

Vehreschild JJ, Bohme A, Cornely OA, Kahl C, Karthaus M, Kreuzer KA et al (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol 25:1709–1718PubMedCrossRef

12.

Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M, Infectious Diseases Working P et al (2013) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 92:433–442PubMedPubMedCentralCrossRef

13.

Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012;1:CD004386.

14.

Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ (2014) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 20(Suppl 3):1–4PubMedCrossRef

15.

Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Kruger W et al (2016) Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 95:1435–1455PubMedPubMedCentralCrossRef

16.

Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M et al (2017) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol

17.

Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O et al (2015) Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 94:1441–1450PubMedPubMedCentralCrossRef

18.

Christopeit MS-H, M; Sprute, R.; Buchheidt, D.; Hentrich, M.; Karthaus, M.; Penack, O.; Ruhnke, M.; Weissinger, F.; Cornely, O.A.; Maschmeyer, G. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autolo-gous hematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Submitted. 2020.

19.

Slavin MA, Lingaratnam S, Mileshkin L, Booth DL, Cain MJ, Ritchie DS et al (2011) Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 41:102–109PubMedCrossRef

20.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 36:3043–3054PubMedCrossRef

21.

Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM (2014) History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol 25:1821–1829PubMedCrossRef

22.

Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190–199PubMedCrossRef

23.

Skoetz N, Bohlius J, Engert A, Monsef I, Blank O, Vehreschild JJ. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. Cochrane Database Syst Rev. 2015:CD007107.

24.

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27:v111–v1v8PubMedCrossRef

25.

Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794–810PubMedCrossRef

26.

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93PubMedCrossRef

27.

Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C et al (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 98:1826–1835PubMedPubMedCentralCrossRef

28.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. JCO2017776211.

29.

Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. (2017) Prevention and treatment of cancer-related infections - NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

30.

Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 98:2402–2409PubMedCrossRef

31.

Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M et al (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44:2069–2076PubMedCrossRef

32.

Assi H, Murray J, Boyle L, Rayson D (2014) Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment. Support Care Cancer 22:3227–3234PubMedCrossRef

33.

Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C et al (2004) CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer. 101:2675–2680PubMedCrossRef

34.

Sasaki T, Takenaka Y, Hayashi T, Yamamoto M, Cho H, Fukusumi T et al (2015) Factors predicting severe infections during chemotherapy in head and neck cancer patients. Acta Otolaryngol 135:1086–1091PubMedCrossRef

35.

Tjan-Heijnen VC, PE P, A A, CH M, J B, J vM et al (2001) Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368PubMedCrossRef

36.

Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH et al (2014) Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci 29:1493–1500PubMedPubMedCentralCrossRef

37.

Chan A, Chen C, Chiang J, Tan SH, Ng R (2012) Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer 20:1525–1532PubMedCrossRef

38.

Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A et al (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 33:844–862PubMedPubMedCentralCrossRef

39.

Benamu E, Montoya JG (2016) Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 29:319–329PubMedCrossRef

40.

Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L (2011) Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 26:1919–1920PubMedPubMedCentralCrossRef

41.

Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C et al (2014) Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Inf Secur 68:321–331

42.

Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110PubMedCrossRef

43.

Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cisnal M et al (2012) Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 19:474–479PubMedCrossRef

44.

Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Calvo M, Arnan M et al (2014) Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Inf Secur 69:417–423

45.

Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39(Suppl 1):S25–S31PubMedCrossRef

46.

Conn JR, Catchpoole EM, Runnegar N, Mapp SJ, Markey KA (2017) Low rates of antibiotic resistance and infectious mortality in a cohort of high-risk hematology patients: a single center, retrospective analysis of blood stream infection. PLoS One 12:e0178059PubMedPubMedCentralCrossRef

47.

Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E et al (2008) Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61:721–728PubMedCrossRef

48.

Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R et al (2015) Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 21:337–343PubMedCrossRef

49.

Weisser M, Theilacker C, Tschudin Sutter S, Babikir R, Bertz H, Gotting T et al (2017) Secular trends of bloodstream infections during neutropenia in 15181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS). Clin Microbiol Infect

50.

Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ (2016) Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - review of the literature from a clinical perspective. Crit Rev Microbiol 42:1–16PubMedCrossRef

51.

Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Hantschel M, Peter S et al (2014) A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 69:3387–3392PubMedCrossRef

52.

De Rosa FG, Motta I, Audisio E, Frairia C, Busca A, Di Perri G et al (2013) Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis 13:563PubMedPubMedCentralCrossRef

53.

Vehreschild MJ, Weitershagen D, Biehl LM, Tacke D, Waldschmidt D, Tox U et al (2014) Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biol Blood Marrow Transplant 20:823–828PubMedCrossRef

54.

Kern WV, Weber S, Dettenkofer M, Kaier K, Bertz H, Behnke M et al (2018) Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. J Inf Secur 77:68–74

55.

Verlinden A, Jansens H, Goossens H, van de Velde AL, Schroyens WA, Berneman ZN et al (2014) Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Eur J Haematol 93:302–308PubMedCrossRef

56.

See I, Freifeld AG, Magill SS (2016) Causative organisms and associated antimicrobial resistance in healthcare-associated, central line-associated bloodstream infections from oncology settings, 2009-2012. Clin Infect Dis 62:1203–1209PubMedCrossRef

57.

Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G et al (2016) Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Inf Secur 73:336–345

58.

Kantele A, Mero S, Kirveskari J, Laaveri T (2017) Fluoroquinolone antibiotic users select fluoroquinolone-resistant ESBL-producing Enterobacteriaceae (ESBL-PE) - data of prospective traveller study. Travel Med Infect Dis

59.

Hakki M, Humphries RM, Hemarajata P, Tallman GB, Shields RK, Mettus RT et al (2019) Fluoroquinolone prophylaxis selects for meropenem-nonsusceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis 68:2045–2052PubMedCrossRef

60.

Saito T, Yoshioka S, Iinuma Y, Takakura S, Fujihara N, Ichinohe T et al (2008) Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. Eur J Clin Microbiol Infect Dis 27:209–216PubMedCrossRef

61.

Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15:e277–e281PubMedCrossRef

62.

Miles-Jay A, Butler-Wu S, Rowhani-Rahbar A, Pergam SA (2015) Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis. Biol Blood Marrow Transplant 21:539–545PubMedCrossRef

63.

Laukens D, Brinkman BM, Raes J, De Vos M, Vandenabeele P (2016) Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiol Rev 40:117–132PubMedCrossRef

64.

Chong Y, Shimoda S, Miyake N, Aoki T, Ito Y, Kamimura T et al (2017) Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis. Infect Drug Resist 10:193–199PubMedPubMedCentralCrossRef

65.

Chong Y, Shimoda S, Yakushiji H, Ito Y, Aoki T, Miyamoto T et al (2014) Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis. PLoS One 9:e85210PubMedPubMedCentralCrossRef

66.

Buelow E, Gonzalez TB, Versluis D, Oostdijk EA, Ogilvie LA, van Mourik MS et al (2014) Effects of selective digestive decontamination (SDD) on the gut resistome. J Antimicrob Chemother 69:2215–2223PubMedCrossRef

67.

Isaac S, Scher JU, Djukovic A, Jimenez N, Littman DR, Abramson SB et al (2017) Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J Antimicrob Chemother 72:128–136PubMedCrossRef

68.

Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 342:967–970PubMedPubMedCentralCrossRef

69.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D et al (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 342:971–976PubMedPubMedCentralCrossRef

70.

Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L et al (2016) Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology. 5:e1150399PubMedPubMedCentralCrossRef

71.

Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER et al (2017) Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol 35:1650–1659PubMedPubMedCentralCrossRef

72.

Weber D, Jenq RR, Peled JU, Taur Y, Hiergeist A, Koestler J et al (2017) Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 23:845–852PubMedPubMedCentralCrossRef

73.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 359:97–103PubMedCrossRef

74.

Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J et al (2019) Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 8:e1568812PubMedPubMedCentralCrossRef

75.

Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T et al (2019) Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncology 5:1774–1778PubMedPubMedCentralCrossRef

76.

Lee YJ, Arguello ES, Jenq RR, Littmann E, Kim GJ, Miller LC et al (2017) Protective factors in the intestinal microbiome against clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis 215:1117–1123PubMedPubMedCentralCrossRef

77.

Harris B, Morjaria SM, Littmann ER, Geyer AI, Stover DE, Barker JN et al (2016) Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplantation. Am J Respir Crit Care Med 194:450–463PubMedPubMedCentralCrossRef

78.

Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L et al (2014) The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 124:1174–1182PubMedPubMedCentralCrossRef

79.

Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A et al (2012) Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55:905–914PubMedPubMedCentralCrossRef

80.

Routy B, Letendre C, Enot D, Chenard-Poirier M, Mehraj V, Seguin NC et al (2017) The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. Oncoimmunology. 6:e1258506PubMedCrossRef

81.

Thackray LB, Handley SA, Gorman MJ, Poddar S, Bagadia P, Briseno CG et al (2018) Oral antibiotic treatment of mice exacerbates the disease severity of multiple flavivirus infections. Cell Rep 22:3440–3453 e6PubMedPubMedCentralCrossRef

82.

Haak BW, Littmann ER, Chaubard JL, Pickard AJ, Fontana E, Adhi F et al (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood. 131:2978–2986PubMedPubMedCentral

83.

Ogimi C, Krantz EM, Golob JL, Waghmare A, Liu C, Leisenring WM et al (2018) Antibiotic exposure prior to respiratory viral infection is associated with progression to lower respiratory tract disease in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 24:2293–2301PubMedPubMedCentralCrossRef

84.

Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C et al (2008) Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 27:53–63PubMedCrossRef

85.

Owattanapanich W, Chayakulkeeree M (2019) Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. Hematology (Amsterdam, Netherlands) 24:362–368

86.

Egan G, Robinson PD, Martinez JPD, Alexander S, Ammann RA, Dupuis LL et al (2019) Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials. Cancer Med 8:4536–4546PubMedPubMedCentralCrossRef

87.

Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K et al (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol 20:1760–1772PubMedPubMedCentralCrossRef

88.

Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020) Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol 104:420–426PubMedCrossRef

89.

Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O et al (2017) Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect

90.

Yemm KE, Barreto JN, Mara KC, Dierkhising RA, Gangat N, Tosh PK (2018) A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia. J Antimicrob Chemother 73:204–211PubMedCrossRef

91.

Modi D, Jang H, Kim S, Surapaneni M, Sankar K, Deol A et al (2017) Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients. Support Care Cancer 25:2593–2601PubMedPubMedCentralCrossRef

92.

Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH et al (2016) Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. Haematologica. 101:1208–1215PubMedPubMedCentralCrossRef

93.

Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE et al (2015) Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21:1808–1814PubMedPubMedCentralCrossRef

94.

Jung SH, Kang SJ, Jang HC, Ahn JS, Yang DH, Lee SS et al (2014) Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. Int J Hematol 100:473–477PubMedCrossRef

95.

Lee SSF, Fulford AE, Quinn MA, Seabrook J, Rajakumar I (2018) Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions. Support Care Cancer 26:1499–1504PubMed

96.

Fernandes R, Mazzarello S, Stober C, Ibrahim MFK, Dudani S, Perdrizet K et al (2018) Primary febrile neutropenia prophylaxis for patients who receive FEC-D chemotherapy for breast cancer: a systematic review. J Glob Oncol 4:1–8PubMed

97.

Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995PubMedCrossRef

98.

Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A et al (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer. 107:1743–1751PubMedCrossRef

99.

Bow EJ, Rayner E, Louie TJ (1988) Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. Am J Med 84:847–854PubMedCrossRef

100.

Mayer K, Hahn-Ast C, Muckter S, Schmitz A, Krause S, Felder L et al (2015) Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia. Support Care Cancer 23:1321–1329PubMedCrossRef

101.

Dekker AW (1987) Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 106:7PubMedCrossRef

102.

Johnson EJ, MacGowan AP, Potter MN, Stockley RK, White LO, Slade RR et al (1990) Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother 25:837–842PubMedCrossRef

103.

Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H et al (2012) Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Int J Antimicrob Agents 39:130–134PubMedCrossRef

104.

von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Dohner H et al (2006) Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 58:891–894CrossRef

105.

Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C (2003) Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 21:4127–4137PubMedCrossRef

106.

Paul M, Borok S, Fraser A, Vidal L, Leibovici L (2005) Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55:436–444PubMedCrossRef

107.

Bow EJ, Rayner E, Louie TJ (1988) Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med 84:847–854PubMedCrossRef

108.

Donnelly JP, Maschmeyer G, Daenen S (1992) Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer (Oxford, England : 1990) 28a:873–878CrossRef

109.

Koh S, Yamada K, Nishimoto M, Hayashi Y, Koh H, Nakashima Y et al (2015) Effectiveness of antibacterial prophylaxis with non-absorbable polymyxin B compared to levofloxacin after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 17:647–654PubMedCrossRef

110.

Weber D, Oefner PJ, Dettmer K, Hiergeist A, Koestler J, Gessner A et al (2016) Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 51:1087–1092PubMedCrossRef

111.

FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. 2016.

112.

FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. US Food and Drug Administration; 2018.

113.

Rote-Hand-Brief zu systemisch und inhalativ angewendeten Fluorchinolonen: Risiko für Aortenaneurysmen und Aortendissektionen German Bundesinstitut für Arzneimittel und Medizinprodukte 2018.

114.

Rote-Hand-Brief zu Fluorchinolon-Antibiotika: Schwerwiegende und anhaltende, die Lebensqualität beeinträchtigende und möglicherweise irreversible Nebenwirkungen. German Bundesinstitut für Arzneimittel und Medizinprodukte; 2019.

115.

Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T et al (2018) Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Inf Secur 76:20–37

116.

Beelen DW, Elmaagacli A, Müller KD, Hirche H, Schaefer UW (1999) Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood. 93:3267–3275PubMedCrossRef

117.

Watson JG, Jameson B, Powles RL, McElwain TJ, Lawson DN, Judson I et al (1982) Co-trimoxazole versus non-absorbable antibiotics in acute leukaemia. Lancet 1:6–9PubMedCrossRef

118.

Bow EJ, Rayner E, Scott BA, Louie TJ (1987) Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration. Antimicrob Agents Chemother 31:551–557PubMedPubMedCentralCrossRef

119.

Daneman N, Sarwar S, Fowler RA, Cuthbertson BH (2013) Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13:328–341PubMedCrossRef

120.

Benus RF, Harmsen HJ, Welling GW, Spanjersberg R, Zijlstra JG, Degener JE et al (2010) Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients. Intensive Care Med 36:1394–1402PubMedPubMedCentralCrossRef

121.

Buelow E, Bello Gonzalez TDJ, Fuentes S, de Steenhuijsen Piters WAA, Lahti L, Bayjanov JR et al (2017) Comparative gut microbiota and resistome profiling of intensive care patients receiving selective digestive tract decontamination and healthy subjects. Microbiome. 5:88PubMedPubMedCentralCrossRef

122.

Bello Gonzalez TDJ, Pham P, Top J, Willems RJL, van Schaik W, van Passel MWJ et al (2017) Characterization of Enterococcus isolates colonizing the intestinal tract of intensive care unit patients receiving selective digestive decontamination. Front Microbiol 8:1596PubMedPubMedCentralCrossRef

123.

Schoovaerts K, Dirix L, Rutten A, Van Schaeren J, Van Herendael B, Van Grieken S et al (2017) Pneumocystis jiroveci pneumonia (PJP) in non-HIV immunocompromised individuals. Acta Clin Belg:1–4

124.

Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG (1974) Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 80:83–93PubMedCrossRef

125.

Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV (1975) Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 36:2004–2009PubMedCrossRef

126.

Sepkowitz KA (2002) Opportunistic infections in patients with and patients without Acquired immunodeficiency syndrome. Clin Infect Dis 34:1098–1107PubMedCrossRef

127.

Stern A, Green H, Paul M, Vidal L, Leibovici L (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. CD005590.

128.

Hughes WT, Price RA, Kim H-K, Coburn TP, Grigsby D, Feldman S (1973) Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr 82:404–415PubMedCrossRef

129.

Martin-Garrido I, Carmona EM, Specks U, Limper AH (2013) Pneumocystis pneumonia in patients treated with rituximab. Chest. 144:258–265PubMedCrossRef

130.

De Castro N, Neuville S, Sarfati C, Ribaud P, Derouin F, Gluckman E et al (2005) Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 36:879–883PubMedCrossRef

131.

Mansharamani NG, Garland R, Delaney D, Koziel H (2000) Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995. Chest. 118:704–711PubMedCrossRef

132.

Maeda T, Babazono A, Nishi T, Matsuda S, Fushimi K, Fujimori K (2015) Quantification of the effect of chemotherapy and steroids on risk of Pneumocystis jiroveci among hospitalized patients with adult T-cell leukaemia. Br J Haematol 168:501–506PubMedCrossRef

133.

Sepkowitz KA (1993) Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 17:416–422CrossRef

134.

Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW et al (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 90:1145–1151PubMedCrossRef

135.

Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D (2007) Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 92:139–140PubMedCrossRef

136.

Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernandez-Ruiz M et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect

137.

Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor-alpha agents). Clin Microbiol Infect

138.

Fernandez-Ruiz M, Meije Y, Manuel O, Akan H, Carratala J, Aguado JM et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction). Clin Microbiol Infect 24(Suppl 2):S2–s9PubMedCrossRef

139.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M et al (2017) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 18:297–311PubMedPubMedCentralCrossRef

140.

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA et al (2017) Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 102:e156–e1e9PubMedPubMedCentralCrossRef

141.

Reinwald M, Silva JT, Mueller NJ, Fortun J, Garzoni C, de Fijter JW et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect

142.

Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891–3897PubMedCrossRef

143.

Keating M, Coutré S, Rai K, Österborg A, Faderl S, Kennedy B et al (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma 4:220–227PubMedCrossRef

144.

Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43:16–24PubMedCrossRef

145.

Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S et al (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473–5480PubMedPubMedCentralCrossRef

146.

Neuwelt AJ, Nguyen TM, Fu R, Bubalo J, Tyson RM, Lacy C et al (2014) Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. CNS Oncol 3:267–273PubMedPubMedCentralCrossRef

147.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

148.

Siegel SE, Nesbit ME, Baehner R, Sather H, Hammond GD (1980) Pneumonia during therapy for childhood acute lymphoblastic leukemia. Am J Dis Child (1960) 134:28–34

149.

Kulke MH, Vance EA (1997) Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 25:215–218PubMedCrossRef

150.

Obeid KM, Aguilar J, Szpunar S, Sharma M, del Busto R, Al-Katib A et al (2012) Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clinical lymphoma, myeloma & leukemia 12:66–69CrossRef

151.

Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM et al (2015) Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat 154:359–367PubMedCrossRef

152.

Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M (2009) Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 88:121–132PubMedCrossRef

153.

Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS (1996) A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 156:177–188PubMedCrossRef

154.

Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P et al (2002) Pneumocystis cariniipneumonia in patients with malignant haematological diseases: 10 years’ experience of infection in GIMEMA centres. Br J Haematol 117:379–386PubMedCrossRef

155.

Molina A, Winston DJ, Pan D, Schiller GJ (2018) Increased incidence of nocardial infections in an era of atovaquone prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant

156.

Di Cocco P, Orlando G, Bonanni L, D'Angelo M, Clemente K, Greco S et al (2009) A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc 41:1201–1203PubMedCrossRef

157.

El-Sadr WM, Luskin-Hawk R, Yurik TM, Walker J, Abrams D, John SL et al (1999) A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 29:775–783PubMedCrossRef

158.

Hughes WT, Dankner WM, Yogev R, Huang S, Paul ME, Flores MA et al (2005) Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis 40:136–145PubMedCrossRef

159.

Chan C, Montaner J, Lefebvre E-A, Morey G, Dohn M, McIvor RA et al (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180:369–376PubMedCrossRef

160.

El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH Jr et al (1998) Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 339:1889–1895PubMedCrossRef

161.

Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24:897–902PubMedCrossRef

162.

Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A (2012) Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transpl 26:E184–E190CrossRef

163.

Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuk F, Regier M et al (2015) Atovaquone for prophylaxis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol 134:146–154PubMedCrossRef

164.

Rodriguez M, Sifri CD, Fishman JA (2004) Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 38:e76–e78PubMedCrossRef

165.

Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH (1998) Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother 32:1004–1007PubMedCrossRef

166.

Robin C, Le MP, Melica G, Massias L, Redjoul R, Khoudour N et al (2017) Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. J Antimicrob Chemother 72:2602–2606PubMedCrossRef

167.

Sangiolo D, Storer B, Nash R, Corey L, Davis C, Flowers M et al (2005) Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 11:521–529PubMedCrossRef

168.

Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He WL et al (1995) A randomized trial of 3 antipneumocystis agents in patients with advanced human-immunodeficiency-virus infection. New Engl J Med 332:693–699PubMedCrossRef

169.

Beumont MG, Graziani A, Ubel PA, MacGregor RR (1996) Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 100:611–616PubMedCrossRef

170.

Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH (2000) Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 6:35–43PubMedCrossRef

171.

Khalaf AM, Hashim MA, Alsharabati M, Fallon K, Cure JK, Pappas P et al (2017) Late-onset cerebral toxoplasmosis after allogeneic hematopoietic stem cell transplantation. The American journal of case reports 18:246–250PubMedPubMedCentralCrossRef

172.

Busemann C, Ribback S, Zimmermann K, Sailer V, Kiefer T, Schmidt CA et al (2012) Toxoplasmosis after allogeneic stem cell transplantation--a single centre experience. Ann Hematol 91:1081–1089PubMedCrossRef

173.

Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kato S et al (2008) No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation. Transpl Infect Dis 10:303–307PubMedCrossRef

174.

Konishi M, Yoshimoto E, Takahashi K, Uno K, Kasahara K, Murakawa K et al (2003) Aerosolized pentamidine prophylaxis against AIDS-related Pneumocystis carinii pneumonia and its short- and long-term effects on pulmonary function in the Japanese. J Infect Chemother 9:178–182PubMedCrossRef

175.

Obaji J, Lee-Pack LR, Gutierrez C, Chan CK (2003) The pulmonary effects of long-term exposure to aerosol pentamidine: a 5-year surveillance study in HIV-infected patients. Chest. 123:1983–1987PubMedCrossRef

176.

Wei CC, Pack LL, Chan CK (1998) Effects of long-term aerosol pentamidine for Pneumocystis carinii prophylaxis on pulmonary function. Chest. 114:742–747PubMedCrossRef

177.

Tullis E, Yu DG, Rawji M, Rachlis A, Hyland R, Chan CK (1992) The long-term effects of aerosol pentamidine on pulmonary function. The Toronto Aerosolized Pentamidine Study (TAPS) Group. Clin Invest Med 15:42–48PubMed

178.

Camus F, de Picciotto C, Lepretre A, Landman R, Girard PM (1991) Pulmonary tolerance of prophylactic aerosolized pentamidine in human immunodeficiency virus-infected patients. Chest. 99:609–612PubMedCrossRef

179.

O’Riordan TG, Smaldone GC (1992) Exposure of health care workers to aerosolized pentamidine. Chest. 101:1494–1499PubMedCrossRef

180.

Balmes JR, Estacio PL, Quinlan P, Kelly T, Corkery K, Blanc P (1995) Respiratory effects of occupational exposure to aerosolized pentamidine. J Occup Environ Med 37:145–150PubMedCrossRef

181.

Hughes WT, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur RJ et al (1977) Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 297:1419–1426PubMedCrossRef

182.

Hughes WT (1987) Pneumocystis carinii pneumonitis. N Engl J Med 317:1021–1023PubMedCrossRef

183.

Olsen SL, Renlund DG, O'Connell JB, Taylor DO, Lassetter JE, Eastburn TE et al (1993) Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation. 56:359–362PubMedCrossRef

184.

Schneider MM, Nielsen TL, Nelsing S, Hoepelman AI, Eeftinck Schattenkerk JK, van der Graaf Y et al (1995) Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis 171:1632–1636PubMedCrossRef

185.

Hirschel B, Lazzarin A, Chopard P, Opravil M, Furrer HJ, Ruttimann S et al (1991) A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 324:1079–1083PubMedCrossRef

186.

Link H, Vohringer HF, Wingen F, Bragas B, Schwardt A, Ehninger G (1993) Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 11:403–406PubMed

187.

Lim MJ, Stebbings A, Lim SJ, Foor K, Hou JZ, Farah R et al (2015) IV pentamidine for primary PJP prophylaxis in adults undergoing allogeneic hematopoietic progenitor cell transplant. Bone Marrow Transplant 50:1253–1255PubMedCrossRef

188.

Curi DA, Duerst RE, Badke C, Bell J, Chaudhury S, Kletzel M et al (2016) IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients. Bone Marrow Transplant 51:1394–1396PubMedCrossRef

189.

Sweiss K, Anderson J, Wirth S, Oh A, Quigley JG, Khan I et al (2018) A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. Bone Marrow Transplant 53:300–306PubMedCrossRef

Title: Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)
Authors: Annika Y. Classen
Larissa Henze
Marie von Lilienfeld-Toal
Georg Maschmeyer
Michael Sandherr
Luisa Durán Graeff
Nael Alakel
Maximilian Christopeit
Stefan W. Krause
Karin Mayer
Silke Neumann
Oliver A. Cornely
Olaf Penack
Florian Weißinger
Hans-Heinrich Wolf
Jörg Janne Vehreschild
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Antibiotic
Neutropenia
Pneumonia
Hematology
Published in: Annals of Hematology / Issue 6/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-021-04452-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial

Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis

Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)

Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma

Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant

A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page